Forbes -- Is the setback Merck is facing on the heart drug vorapaxar the fault of Kenneth C. Frazier, 55, who took over as the company’s chief executive less than a month ago? Erik M. Gordon, a clinical assistant professor at the University of Michigan’s Ross School of Business, thinks so. After the bad news on vorapaxar, which Merck got from its $41 billion acquisition of Schering-Plough, I asked if the news invalidated the merger. Gordon replied, via email:
